CLINICAL TRIALS PROFILE FOR GEMTUZUMAB OZOGAMICIN
✉ Email this page to a colleague
All Clinical Trials for Gemtuzumab Ozogamicin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003131 ↗ | CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse | Completed | Pfizer | Phase 2 | 1997-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating patients with acute myeloid leukemia in first relapse. |
| NCT00003673 ↗ | CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse | Completed | Pfizer | Phase 2 | 1998-03-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating older patients who have acute myeloid leukemia that has recurred for the first time following at least 3 months of complete remission. |
| NCT00005962 ↗ | Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia | Completed | National Cancer Institute (NCI) | Phase 2 | 2000-07-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining more than one drug or combining monoclonal antibody with chemotherapy may kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia. PURPOSE: Randomized phase II trial to compare the effectiveness of three treatment regimens in treating patients who have relapsed or refractory acute myelogenous leukemia. |
| NCT00005962 ↗ | Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia | Completed | Eastern Cooperative Oncology Group | Phase 2 | 2000-07-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining more than one drug or combining monoclonal antibody with chemotherapy may kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia. PURPOSE: Randomized phase II trial to compare the effectiveness of three treatment regimens in treating patients who have relapsed or refractory acute myelogenous leukemia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Gemtuzumab Ozogamicin
Condition Name
Clinical Trial Locations for Gemtuzumab Ozogamicin
Trials by Country
Clinical Trial Progress for Gemtuzumab Ozogamicin
Clinical Trial Phase
Clinical Trial Sponsors for Gemtuzumab Ozogamicin
Sponsor Name
